Fluvoxamine for Adults With Mild to Moderate COVID-19
Status:
Suspended
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This clinical trial aims to determine if fluvoxamine, a selective serotonin reuptake
inhibitor with high affinity for the sigma-1 receptor, can be used in mild to moderate
COVID-19 to prevent the progression to severe COVID-19. Fluvoxamine is an anti-depressant
drug approved by the FDA for the treatment of obsessive-compulsive disorder and has a
potential for immune modulation as a sigma-1 receptor agonist. The investigational use of
fluvoxamine for the treatment of COVID-19 is approved by the South Korean Ministry of Food
and Drug Safety.
This study is performed fully-remotely at COVID-19 community treatment centers, temporary
facilities in Seoul, Korea, to accommodate and monitor asymptomatic to moderately symptomatic
case-patients who do not require hospital admission.